Clinical Trial Safety and Risk Mitigation Planning

The contract pertains to the development of comprehensive safety protocols for ibogaine clinical trials, with a focus on mitigating risks associated with its use in therapeutic settings. Key components include the implementation of rigorous cardiotoxicity monitoring systems to detect and manage potential cardiac adverse events, detailed assessments of drug interactions to prevent harmful combinations, and the establishment of dose de-escalation strategies to ensure patient safety across varying treatment phases. These protocols are intended to support the responsible and scientifically sound advancement of ibogaine research, particularly in contexts where safety concerns have historically hindered clinical progress. This subcontract is issued under the auspices of the Advanced Research Projects Agency for Health, a division of the Department of Health and Human Services, reflecting a federal commitment to advancing innovative but high-risk therapeutic modalities. The work is to be completed in response to a solicitation posted on August 5, 2026, with proposals due by October 15, 2026. The NAICS code 541690 indicates the nature of the work involves other scientific and technical consulting services, aligning with the specialized expertise required for designing and validating complex clinical safety frameworks. The place of performance and point of contact details are unspecified, suggesting flexibility in execution location while maintaining strict adherence to federal safety and compliance standards.